PharmAla Completes Historic First Shipment of MDMA and Psilocybin to Cortexa
07 nov. 2023 08h55 HE
|
PharmAla Biotech
PharmAla completes the historic first shipment of MDMA and Psilocybin to its Australian Joint Venture, Cortexa, for use in commercial patient treatments
PharmAla Receives First Office Action for PharmAla-1 PCT Filing
25 sept. 2023 08h55 HE
|
PharmAla Biotech
PharmAla has recieved a positive First Office Action on its novel P-1 Molecule from the Patent Cooperation Treaty
PharmAla Begins Trading on OTCQB
06 sept. 2023 08h55 HE
|
PharmAla Biotech
VANCOUVER, British Columbia, Sept. 06, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTCQB:PMBHF), a biotechnology company focused on the...
PharmAla Ships MDMA to Mind Medicine Australia and Orygen Institute
10 août 2023 08h30 HE
|
PharmAla Biotech
VANCOUVER, British Columbia, Aug. 10, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:PMBHF), a biotechnology company focused on the research,...
PharmAla Files Patent for Novel MDXX Molecule PharmAla-1
31 juil. 2023 08h30 HE
|
PharmAla Biotech
VANCOUVER, British Columbia, July 31, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:PMBHF), a biotechnology company focused on the research,...
PharmAla Received Guidance on ALA-002 from MHRA; Launches Clinical Program with University of Sydney
20 juil. 2023 09h07 HE
|
PharmAla Biotech
VANCOUVER, British Columbia, July 20, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:PMBHF), a biotechnology company focused on the research,...
Cortexa Makes First Drug Order for Australian Commercial Market
04 juil. 2023 08h55 HE
|
PharmAla Biotech
VANCOUVER, British Columbia, July 04, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:PMBHF), a biotechnology company focused on the research,...
PharmAla Biotech Receives Export Permit to Ship GMP LaNeo MDMA to the University of Sydney
16 juin 2023 09h00 HE
|
PharmAla Biotech
VANCOUVER, British Columbia, June 16, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:PMBHF, a biotechnology company focused on the research,...
PharmAla Biotech announces Non-Brokered Private Placement Offering of up to an Aggregate of $5,000,000
12 juin 2023 20h07 HE
|
PharmAla Biotech
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, June 12, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (the...
USFDA Approves LaNeo MDMA for Clinical Trial Use in the United States
09 juin 2023 15h48 HE
|
PharmAla Biotech
Approved Study to Examine Tolerability of MDMA in Schizophrenia at UCLA VANCOUVER, British Columbia, June 09, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla”)(CSE:...